Your session is about to expire
← Back to Search
Noninvasive Brain Stimulation
Transcranial Direct Current Stimulation for Pediatric OCD
N/A
Recruiting
Led By Daniel Geller, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Outpatient youth between the ages 10-17 years
Be younger than 18 years old
Must not have
Current clinically significant suicidality or individuals who have engaged in suicidal behaviors within 6 months will be excluded and referred for appropriate clinical care.
Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, ventriculoperitoneal (VP) shunt, pacemakers.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing tDCS, a method using a small electrical current on the scalp, in children with OCD. The goal is to see if it can help normalize their brain function and improve symptoms. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that has been extensively investigated in adults with psychiatric disorders, including depression and anxiety.
Who is the study for?
This trial is for kids aged 10-17 with moderate to severe OCD, as measured by a specific scale. They must have an IQ of at least 85 and speak English. Kids can't join if they've had recent medication changes, certain mental health diagnoses, are underweight, pregnant or nursing, or have metal implants in the head/neck.
What is being tested?
The study tests how transcranial direct current stimulation (tDCS) affects brain processes related to OCD in children. It's non-invasive and aims to modulate neural activity that contributes to the disorder.
What are the potential side effects?
While tDCS is generally considered safe, potential side effects may include mild itching, tingling or discomfort at the electrode sites during stimulation. There could also be fatigue or headache after treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 10 and 17 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had suicidal thoughts or behaviors in the last 6 months.
Select...
I don't have epilepsy, metal implants in my head/neck, brain devices, or a pacemaker.
Select...
I do not have a severe illness that could hospitalize me during the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Fear Extinction Recall Task
Change in Sequential Spaceship Task
Change in Stop Signal Task
Secondary study objectives
Change in EEG readings
Side effects data
From 2021 Phase 2 & 3 trial • 160 Patients • NCT024834682%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Inhibitory Control/ Goal-Orientated vs Habit-Based BehaviorExperimental Treatment1 Intervention
This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
Group II: Inhibitory Control/ Fear ExtinctionExperimental Treatment1 Intervention
This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Direct Current Stimulation (tDCS) and similar neuromodulation treatments, such as repetitive Transcranial Magnetic Stimulation (rTMS) and Electroconvulsive Therapy (ECT), work by modulating neuronal activity and connectivity in the brain. tDCS uses low electrical currents to stimulate specific brain regions, potentially enhancing or inhibiting neuronal activity to improve symptoms. rTMS uses magnetic fields to induce electrical currents in the brain, targeting areas involved in mood regulation. ECT involves brief electrical stimulation to induce controlled seizures, which can reset abnormal brain activity patterns.
These treatments are important for mental health disorder patients as they offer alternative options when traditional pharmacotherapy is ineffective, providing potential relief from symptoms by directly influencing brain function.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,015 Previous Clinical Trials
13,309,324 Total Patients Enrolled
Daniel Geller, MDPrincipal InvestigatorMassachusetts General Hospital
Joan Camprodon, MD, PhD, MPHPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
948 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 10 and 17 years old.I am a young person with symptoms of hoarding.You have been diagnosed with certain mental health conditions like conduct disorder, autism, bipolar disorder, ADHD, Tourette's syndrome, schizophrenia, or schizoaffective disorders based on DSM-V criteria.I have not had suicidal thoughts or behaviors in the last 6 months.I don't have epilepsy, metal implants in my head/neck, brain devices, or a pacemaker.My mental health medication has been stable for at least 6 weeks.Your body mass index (BMI) is too low.I do not have a severe illness that could hospitalize me during the study.You are addicted to drugs or alcohol (excluding tobacco).I am currently not in psychotherapy for OCD, but may be receiving it for other mental health issues.I haven't started new antidepressants, antipsychotics, or diets in the weeks before joining the study.
Research Study Groups:
This trial has the following groups:- Group 1: Inhibitory Control/ Fear Extinction
- Group 2: Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger